MP or MPT as initial therapy for multiple myeloma.31
| Response Category . | MPT (n= 129) . | MP (n= 126) . |
|---|---|---|
| Abbreviations: MP, melphalan and prednisone; MPT, melphalan and prednisone with thalidomide; n, number of patients in each cohort | ||
| Overall response rate (at least a partial response) | 98 (76.0%) | 60 (47.6%) |
| Complete response | 20 (15.5%) | 3 (2.4%) |
| Partial response | 78 (60.4%) | 57 (45.2%) |
| Near-complete response | 16 (12.4%) | 6 (4.8%) |
| Very good partial response | 11 (8.5%) | 6 (4.8%) |
| Partial response | 51 (39.5%) | 45 (35.7%) |
| Minimal response | 7 (5.4%) | 21 (16.7%) |
| No response | 7 (5.4%) | 19 (15.1%) |
| Progressive disease | 10 (7.8%) | 21 (16.7%) |
| Not available | 7 (5.4%) | 5 (4.0%)‘ |
| Response Category . | MPT (n= 129) . | MP (n= 126) . |
|---|---|---|
| Abbreviations: MP, melphalan and prednisone; MPT, melphalan and prednisone with thalidomide; n, number of patients in each cohort | ||
| Overall response rate (at least a partial response) | 98 (76.0%) | 60 (47.6%) |
| Complete response | 20 (15.5%) | 3 (2.4%) |
| Partial response | 78 (60.4%) | 57 (45.2%) |
| Near-complete response | 16 (12.4%) | 6 (4.8%) |
| Very good partial response | 11 (8.5%) | 6 (4.8%) |
| Partial response | 51 (39.5%) | 45 (35.7%) |
| Minimal response | 7 (5.4%) | 21 (16.7%) |
| No response | 7 (5.4%) | 19 (15.1%) |
| Progressive disease | 10 (7.8%) | 21 (16.7%) |
| Not available | 7 (5.4%) | 5 (4.0%)‘ |